News

The key investment targets of the biopharmaceutical fund of US$50 million raised is for Biosyngen biopharmaceutical technology transfer platform and to incubate companies. Biosyngen has been an angel

The submission is based on results from the Phase 3 E1912 study – designed and conducted by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and sponsored by the National

Reblozyl is an erythroid maturation agent, which was co-developed by Celgene and Acceleron Pharma. According to Celgene, the FDA-approved drug is a new class of therapy that has

The OLYMPUS trial compared roxadustat to placebo while the ROCKIES trial compared roxadustat to epoetin alfa. The results were presented today during two oral sessions at the American

The company has submitted marketing authorisation applications (MAAs) to the EMA to prevent Ebola Virus Disease (EVD) caused by Zaire ebolavirus species. Janssen has submitted two MAAs in

Takeda’s dengue vaccine candidate demonstrated protection against virologically-confirmed dengue (VCD), the trial primary endpoint, in children ages four to 16 years. Vaccine efficacy (VE) was 80.2% (95% confidence

SB11, a biosimilar candidate referencing LUCENTIS (ranibizumab), is undergoing phase 3 clinical trial, while SB15, a biosimilar candidate referencing EYLEAiii (aflibercept), is in pre-clinical development. In addition, the

Mechanistic data on AXA4010 will be presented at the American Society of Hematology’s (ASH) 2019 Annual Meeting. Additionally, the company has initiated enrollment of subjects with sickle cell

Both firms will also sign a five-year research agreement to use Regeneron’s VelociSuite technologies to jointly design and validate Vesicular Stomatitis Virus (VSV)-based oncolytic virus treatments. Under the